The latest financial statement is for the quarter ending 2025-12-27.
| Cash Flow | 2025-12-27 | 2025-09-27 | 2025-06-28 |
|---|---|---|---|
| Net income | 44,740 | 38,684 | 34,031 |
| Depreciation and amortization | 27,385 | 28,255 | 28,758 |
| Amortization of fair value inventory step-up | 1,323 | 2,055 | 2,436 |
| Share-based compensation expense | 7,799 | 7,589 | 9,312 |
| Impairment of intangible assets | 716 | 8,584 | - |
| Gain on repurchase of convertible senior notes, net | 0 | 0 | 0 |
| Gains on sales of property, plant and equipment | 218 | 75 | 243 |
| Deferred income taxes | -2,062 | -725 | -3,231 |
| Other non-cash operating activities | 2,072 | 865 | 1,814 |
| Change in accounts receivable | -11,058 | 7,259 | -3,557 |
| Change in inventories | -13,841 | -21,762 | -3,296 |
| Change in prepaid income taxes | 1,784 | 210 | -3,346 |
| Change in other assets and other liabilities | 4,610 | 5,903 | 17,785 |
| Change in accounts payable and accrued expenses | -6,696 | 17,699 | -47,896 |
| Net cash provided by operating activities | 93,564 | 111,321 | 17,395 |
| Capital expenditures | 6,349 | 5,016 | 3,754 |
| Non-cash transfers from inventory to property, plant and equipment for haemonetics equipment | -13,444 | -17,689 | -11,460 |
| Acquisitions | 0 | 0 | 0 |
| Proceeds from sale of property, plant and equipment | 432 | 120 | 297 |
| Other investments | 10,105 | 7,883 | 18,083 |
| Net cash used in investing activities | -29,466 | -30,468 | -33,000 |
| Proceeds from issuance of convertible notes | 0 | 0 | 0 |
| Repurchase of convertible senior notes | 0 | 0 | 0 |
| Purchase of capped call related to convertible notes | 0 | 0 | 0 |
| Term loan borrowings | 0 | 0 | 0 |
| Term loan redemption | 0 | 0 | 0 |
| Payments on revolving facility | 0 | 0 | 0 |
| Repayment of term loan borrowings | 1,563 | 1,562 | 1,563 |
| Debt issuance costs | 0 | 0 | 0 |
| Share repurchases | 0 | 75,000 | - |
| Proceeds from employee stock purchase plan | 2,623 | 0 | 3,476 |
| Proceeds from exercise of stock options | 1,147 | 63 | 462 |
| Cash used to net share settle employee equity awards | 160 | 14 | 4,781 |
| Other financing activities | -14 | -39 | -36 |
| Net cash (used in) provided by financing activities | 2,033 | -76,552 | -2,442 |
| Effect of exchange rates on cash and cash equivalents | 810 | -773 | 4,182 |
| Net change in cash and cash equivalents | 66,941 | 3,528 | -13,865 |
| Cash and cash equivalents at beginning of period | 296,426 | 306,763 | - |
| Cash and cash equivalents at end of period | 363,367 | 296,426 | - |
HAEMONETICS CORP (HAE)
HAEMONETICS CORP (HAE)